The health data company Truveta, in collaboration with Regeneron and Illumina, and 17 major U.S. health systems, has launched the Truveta Genome Project.

Truveta has raised $320 million to launch the Truveta Genome Project, aiming to sequence the exomes of up to 10 million participants. In collaboration with Regeneron, Illumina, and 17 U.S. health systems, the project will create a diverse genetic database linked to de-identified medical records. Using AI and Microsoft Azure, the initiative seeks to advance drug discovery and personalized healthcare. Regeneron invested $119.5 million, and Illumina contributed $20 million in the funding round.

Seattle-based health data company Truveta secured $320 million in funding to launch the Truveta Genome Project, aiming to create the largest and most diverse genomic dataset. The investment, from 17 health systems, Illumina, and Regeneron, elevates Truveta's valuation to over $1 billion. Regeneron will sequence exomes of 10 million volunteers. Truveta's total funding is nearly $500 million, with Microsoft as the exclusive cloud provider for the project.